Article Versions Notes

Gerotziafas GT, Fotiou D, Sergentanis TN, Papageorgiou L, Fareed J, Falanga A, Sabbah M, Garderet L, Terpos E, Elalamy I, et al. Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. Hemato. 2022; 3(1):188-203. https://doi.org/10.3390/hemato3010016

Gerotziafas, Grigorios T., Despina Fotiou, Theodoros N. Sergentanis, Loula Papageorgiou, Jawed Fareed, Anna Falanga, Michèle Sabbah, Laurent Garderet, Evangelos Terpos, Ismail Elalamy, and et al. 2022. "Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study" Hemato 3, no. 1: 188-203. https://doi.org/10.3390/hemato3010016

Gerotziafas, G. T., Fotiou, D., Sergentanis, T. N., Papageorgiou, L., Fareed, J., Falanga, A., Sabbah, M., Garderet, L., Terpos, E., Elalamy, I., Van Dreden, P., & Dimopoulos, M. A. (2022). Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. Hemato, 3(1), 188-203. https://doi.org/10.3390/hemato3010016